Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status

Diagnostic Pathology

Mee-Sook Roh³  Dong-Hoon Shin¹  Woo-Jeong Lee⁴  Chang-Hun Lee⁴  Min Gyoung Pak² 

[1] Department of Pathology, School of Medicine, Pusan National University, Yangsan, Republic of Korea;Department of Pathology, Dong-A University Hospital, Busan, Republic of Korea;Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea;Department of Pathology and Medical Research Institute, Pusan National Univeristy Hospital, Busan 602-739, Republic of Korea

关键词: Epidermal growth factor receptor;    NSCLC;    miR-210;    miR-183;    miR-34c;    miRNA;   

Others  :  1219336
DOI  :  10.1186/s13000-015-0339-4

 received in 2015-05-19, accepted in 2015-06-27,  发布年份 2015

【 摘 要 】

Background

Lung cancer is the leading cause of cancer mortality, despite development of therapeutic strategies. Altered expression of microRNAs(miRNAs) in human malignancies have been well recognized as diagnostic and prognostic indicators, including lung cancer. This study aims to delineate the clinicopathologic significance of three unique miRNAs in adenocarcinoma according to major sensitive EGFR mutation status.

Methods

One-hundred and three formalin-fixed paraffin-embedded (FFPE) tissues were collected from lung adenocarcinoma patients who underwent surgery and epidermal growth factor receptor (EGFR) mutation study. The samples were divided into three groups which include EGFR mutation in exons 19 and 21 and wild type. Some representative cases from each group were profiled using commercial miRNA microarray plates. Three significant miRNAs were selected and they were validated by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), using collective cases of FFPE samples.

Results

We identified three microRNAs (miR-34c, miR-183, and miR-210) which showed significantly altered expression in all groups of lung adenocarcinoma by microarray study. Compared to normal control lung tissue, down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups (p < 0.05 for each). We validated the expression of three miRNAs by qRT-PCR. Expression levels of miR-34c, miR-183, and miR-210 were significantly different between normal control group and cancer groups (p = 0.034, <0.000, and 0.036, respectively). Moreover, expression level of miR-183 was significantly higher in EGFR mutation groups than wild type group (p = 0.028). Higher expression levels of three miRNAs were positively related to poor tumor differentiation. Increased expression of miR-183 was positively associated with lymphovascular invasion (p = 0.037). Aberrant expression of miR-210 was independently associated with T stage (p = 0.019), and TNM stage (p = 0.007). However, there was noted a limited statistical significance. In EGFR exon 19 mutation group, miR-34c high expression group showed poor overall survival than low expression one by univariate Kaplan-Meier method. (p = 0.035).

Conclusions

Here, we show that miR-34c may act as a potential tumor suppressor gene and miR-183 and miR-210 have a potential oncogenic role in pulmonary adenocarcinoma. This study also suggests different miRNA expression between EGFR mutation group and wild type group. Consequently, further studies of the biology of miRNAs may lead to diagnostic and prognostic biomarkers in pulmonary adenocarcinoma.

【 授权许可】

   
2015 Pakc et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
• [2]Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED et al.. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011; 17(7):1875-1882.
• [3]Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302(1):1-12.
• [4]Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA et al.. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008; 19(6):1053-1059.
• [5]Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y et al.. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-1726.
• [6]Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013; 329(2):125-136.
• [7]Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al.. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-198.
• [8]Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH et al.. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012; 18(13):3658-3667.
• [9]Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al.. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-13311.
• [10]Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al.. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-844.
• [11]Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al.. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-1043.
• [12]Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y et al.. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013; 30(4):750-013-0750-1.
• [13]Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010; 41(1):20-25.
• [14]Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-1108.
• [15]Shepherd FA. Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol. 2008; 26(15):2426-2427.
• [16]Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al.. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-246.
• [17]Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al.. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-792.
• [18]He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al.. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-1134.
• [19]He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007; 7(11):819-822.
• [20]Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH et al.. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009; 15(4):1177-1183.
• [21]Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D, Ceder Y et al.. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer. 2010; 127(12):2768-2776.
• [22]Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2013; 32(3):341-351.
• [23]Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009; 460(7254):529-533.
• [24]Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007; 67(18):8433-8438.
• [25]Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52(17):4828-4831.
• [26]Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000; 6(10):4055-4063.
• [27]Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y et al.. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 2000; 7(3):603-607.
• [28]Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009; 45(12):2197-2206.
• [29]Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010; 70(23):9570-9580.
• [30]Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011; 11:393-2407-11-393.
• [31]Xu F, Zhang H, Su Y, Kong J, Yu H, Qian B. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clin Transl Oncol. 2014; 16(11):980-985.
• [32]Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T et al.. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009; 69(8):3256-3261.
• [33]Wang Y, Wang X, Zhang J, Sun G, Luo H, Kang C et al.. MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol. 2012; 106(2):217-224.
• [34]Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002; 193(3):287-292.
• [35]Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006; 13(2):115-124.
• [36]Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S et al.. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One. 2011; 6(6): Article ID e20980
• [37]Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K et al.. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011; 18(3):465-478.
• [38]Devlin C, Greco S, Martelli F, Ivan M. miR-210: More than a silent player in hypoxia. IUBMB Life. 2011; 63(2):94-100.
• [39]Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010; 29(30):4362-4368.